EUVIMEDOpdag EUVIMED
Crossref

Pharmacogenomic testing for CYP2C19 and CYP2D6 in cyclic vomiting syndrome

Milan Patel, Omeed Partovi, Katja Karrento, Zhuping Garacchi, Gokulakrishnan Balasubramanian, Thangam Venkatesan iD

Neurogastroenterology & Motility · 2024

DOI: 10.1111/nmo.14705 ↗

At a glance

Journal article in Neurogastroenterology & Motility, 2024. Written by Milan Patel and 5 co-authors. Institution: Medical College of Wisconsin, Milwaukee, Wisconsin, USA. Major MEDLINE topics: Pharmacogenomic Testing, Cytochrome P-450 CYP2D6. Cited 3 times so far (Crossref); 29 references. Funded by: Digestive Diseases Center, Medical College of Wisconsin.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

Amitriptyline (AT) is recommended as first‐line prophylactic therapy in patients with cyclic vomiting syndrome (CVS). However, significant side effects limit its use and dosing is based on trial and error. Though the Clinical Pharmacogenetic Implementation Consortium (CPIC) Guidelines recommend dosing for AT based on CY2D6 and CYP2C19 genotype profile, this is not followed in clinical practice.

Methods

This pilot study determined CYP2C19 and CYP2D6 genotypes and ascertained its association with adverse drug reactions (ADRs), clinical response, and serum concentration of AT and nortriptyline in a well‐characterized cohort of adults with CVS. Key Results Of 46 subjects with CVS, age 33 ± 12 years, 61% female, 85% Caucasian, a third (33%) had normal CYP2C19 metabolizer status, while 4% were poor, and 43% were ultrarapid metabolizers. Most (61%) had normal CYP2D6 genotype while 9% were poor and 2% were ultra‐rapid metabolizers. There was no statistically significant association between genotype and ADRs, clinical response or serum drug concentration. There was a trend towards significance between genotype and clinical response, with 64% of responders having normal CYP2D6 metabolism versus 36% of nonresponders ( p = 0.06). ADRs were encountered in 46% of patients with 28% discontinuing the medication as a result. Conclusions and Inferences A subset of patients with CVS have dysfunctional alleles of CYP2C19 and CYP2D6. Larger prospective studies to evaluate the clinical impact of pharmacogenomic testing in CVS are needed. This has the potential to optimize clinical management, predict ADRs and allow for personalized therapy.

Subjects

MeSH terms (MEDLINE)

Pharmacogenomic TestingCytochrome P-450 CYP2D6AdultCytochrome P-450 CYP2C19FemaleHumansMiddle AgedMaleYoung AdultProspective StudiesPilot ProjectsVomitingGenotypeAmitriptyline

Author keywords

amitriptylinecyclic vomitingcytochrome P450pharmacogenomics

Substances

Cytochrome P-450 CYP2D6Cytochrome P-450 CYP2C19AmitriptylineCYP2C19 protein, human

Authors and institutions

  • Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
  • The Ohio State University, Columbus, Ohio, USA.

ORCID profiles: Thangam Venkatesan

Funding

  • Digestive Diseases Center, Medical College of Wisconsin

Cite

APA

Patel, M., Partovi, O., Karrento, K., Garacchi, Z., Balasubramanian, G., & Venkatesan, T. (2024). Pharmacogenomic testing for CYP2C19 and CYP2D6 in cyclic vomiting syndrome. Neurogastroenterology & Motility. https://doi.org/10.1111/nmo.14705

Vancouver

Patel M, Partovi O, Karrento K, Garacchi Z, Balasubramanian G, Venkatesan T. Pharmacogenomic testing for CYP2C19 and CYP2D6 in cyclic vomiting syndrome. Neurogastroenterology & Motility. 2024. doi:10.1111/nmo.14705

BibTeX
@article{Patel2024,
  author = {Patel, Milan and Partovi, Omeed and Karrento, Katja and Garacchi, Zhuping and Balasubramanian, Gokulakrishnan and Venkatesan, Thangam},
  title = {Pharmacogenomic testing for CYP2C19 and CYP2D6 in cyclic vomiting syndrome},
  journal = {Neurogastroenterology & Motility},
  year = {2024},
  doi = {10.1111/nmo.14705}
}
Start for free →